Sweden's Tomas Salmonson to chair EMA's CHMP
This article was originally published in SRA
Tomas Salmonson has been elected as the new chair of the European Medicines Agency's key scientific committee, the CHMP1.
You may also be interested in...
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
The EU network of health technology assessment bodies says it is seeing the benefit of systematically involving patients when companies approach it for early scientific advice on evidence generation.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.